IMRX
IMRX clinical trials: Immuneering Corp
Every trial on ClinicalTrials.gov where Immuneering Corp is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 4
- Trials linked
- 4
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
IMRX on the catalyst calendar · IMRX registry changes
- Primary completion May 2029Sponsor estimatePhase 2NCT07946848Phase 2 Study to Evaluate Dose Optimization and Anti-tumor Activity of Atebimetinib in Participants With Advanced or Metastatic NSCLC.Immuneering Corporation · NSCLC (Advanced Non-small Cell Lung Cancer)Not yet recruitingIMRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2028Sponsor estimatePhase 3NCT07562152Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaImmuneering Corporation · Pancreatic CancerRecruitingIMRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2027Sponsor estimatePhase 1/Phase 2NCT05585320A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid TumorsImmuneering Corporation · Advanced Solid TumorActive, not recruitingIMRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 30, 2025ActualPhase 1/Phase 2NCT06208124A Study of IMM-6-415 in RAS/RAF Mutant Solid TumorsImmuneering Corporation · Advanced Solid Tumor (Phase 1)CompletedIMRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 4 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner